BLOCK-COPD
2019
Beta-Blockers for the Prevention of Acute Exacerbations of COPD
In 532 patients with moderate-to-severe COPD without cardiac indication for β-blockade, metoprolol succinate did not reduce time to first exacerbation and increased severe exacerbations compared with placebo.
Result
Efficacy: Time to first COPD exacerbationHR 1.05 · P = 0.66
Below 1 favours metoprolol succinate, above 1 favours placebo.
Also reported: Severe exacerbations HR 1.91 (95% CI 1.29–2.83).
- Subtopic
- β-blocker safety
- Design
- Multicentre RCT, stopped early
- Relevance
- Important: one of several pillars.
- Source
- Dransfield MT, et al. N Engl J Med. 2019;381(24):2304-2314.doi 10.1056/NEJMoa1908142
Discussion & critique
Prophylactic β-blockade is harmful in COPD without a cardiac indication; informs cardiology co-management.